Asking the Right Questions at the Right Time
Why evidence decisions made in early development shape launch success
In the world of clinical development, by the time products approach launch, key evidence generation decisions are typically already made. But teams regularly face evidence gaps that can translate into delays, increased spend, or even failure due to limited adoption or market access.
Real-world evidence (RWE) can play a critical role in securing success across the product lifecycle. However, data show that many organizations still establish integrated evidence generation plans too late in development, limiting their ability to shape strategy and impact outcomes.
This Insight Brief explores how aligning real‑world evidence strategies with clinical development plans from the early phases can help your teams reduce risk, improve decision‑making, and ensure the right evidence is available when it matters most.
Access this content for strategic insights into:
- Key strategic RWE use cases throughout the product lifecycle
- Where your approach to integrated evidence planning aligns with wider industry trends
- How an early, cross‑functional integrated evidence generation plan (IEGP) supports clinical, regulatory, and commercial success.
For senior leaders overseeing portfolios, pipelines, or launches, earlier evidence planning is not an operational detail — it’s a strategic lever that shapes regulatory confidence, market access, and commercial viability.
Talk to IQVIA Sales about your evidence planning needs
If you would like to discuss a specific business need, you can request a conversation with an IQVIA sales representative. Completing this form is optional and not required to access downloadable content.
